You are here

CD34+ Therapy Improves CKD Outcomes

A new STEM CELLS Translational Medicine article from researchers led by Hon‐Kan Yip (Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan) reports on the results of a randomized, open‐label, controlled phase II clinical trial to investigate the safety, efficacy, and outcomes of intrarenal artery infusion of autologous peripheral‐blood‐derived CD34+ endothelial progenitor cells for patients with chronic kidney disease (CKD). In summary. Yang et al. discovered the overall safety CD34+ cell therapy and established that this therapeutic approach improved one‐year outcomes.